ELVN — Enliven Therapeutics Share News
0.000.00%
Last trade - 00:00US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group
U.S. STOCKS ON THE MOVE-SpaceX, SharonAI, Medline
Enliven soars after boosted equity raise for leukemia drug
U.S. STOCKS ON THE MOVE-SpaceX, SharonAI, Medline
U.S. STOCKS ON THE MOVE-Adobe, Enliven Therapeutics,SpaceX
Enliven falls after $400 mln equity raise to fund leukemia drug
Brief: Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share
Brief: Enliven Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Enliven Therapeutics slips on $250 mln equity offering
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte
Enliven rises as leukemia drug shows promising early-stage data
Brief: Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data
Brief: Enliven Therapeutics - Increases Authorized Common Stock To 200 Million Shares Effective June 9, 2026 - SEC Filing